Veristat Acquires SFL (Solutions for Life Sciences)

Veristat Acquires SQN Clinical

February 25, 2021

Healthcare Services

Veristat acquired SQN Clinical to expand its biometrics capabilities and strengthen its European footprint. The acquisition adds more than 80 employees and integrates SQN Clinical's clinical data management, biostatistics and project management capabilities into Veristat's global CRO services.

Veristat Acquires Instat Clinical Research

October 19, 2023

Healthcare Services

Veristat, a full-service clinical research organization, has acquired Instat Clinical Research, a biometrics-focused CRO with teams in the United States and India. The deal expands Veristat's biometrics, data management, biostatistics, and statistical programming capabilities while adding offshore capacity to enable round-the-clock support for clinical studies.

Verista Acquires ILB Enterprises

May 31, 2024

Healthcare Services

Verista has acquired ILB Enterprises, a New Jersey–based life sciences consulting firm specializing in pharmacovigilance, safety compliance, program and project management. The deal, led by Verista's private equity sponsor Lightview Capital, expands Verista's capabilities across compliance, automation and validation and strengthens its Mid‑Atlantic life sciences services footprint.

Veristat Acquires The Clinical Trial Company Ltd (TCTC Group)

January 6, 2020

Healthcare Services

Veristat, a full-service CRO based in Southborough, Massachusetts, has acquired The Clinical Trial Company Ltd (TCTC Group), a Europe-headquartered contract research organization. The deal expands Veristat's European footprint and adds TCTC's expertise in gene and cell therapy, CNS and orphan disease clinical trials to Veristat's service offering.

BioLife Solutions Acquires SciSafe

September 21, 2020

Healthcare Services

BioLife Solutions, Inc. (NASDAQ: BLFS) has entered into a definitive agreement to acquire SciSafe, a privately held multi-facility biostorage provider serving the cell and gene therapy and pharmaceutical industries. BioLife will pay $15 million cash and $15 million in newly issued BioLife common shares for 100% of SciSafe, with up to 626,000 additional shares earnable based on revenue milestones; the deal is expected to close on September 30.

In Vitro Sciences (Sverica) Partners with InVia Fertility Specialists

August 26, 2020

Healthcare Services

In Via Fertility Specialists has entered a partnership with In Vitro Sciences, a portfolio company of Sverica Capital Management, with Dresner Partners advising InVia on the transaction. InVia — a four-location fertility clinic group in the Chicagoland area with an on-site embryology lab and three reproductive endocrinologists — will gain strategic, operational and financial resources to support growth and enhance patient care.